## **Special Issue**

# Neuromodulating Bioactive Cerebral Pathways as Potential Cognitive Therapeutics

## Message from the Guest Editors

Due to the ageing population and the development of mental illnesses linked to mutations in society, the question of cognitive disorders holds a major stake in the next decades. Even if there have been many disappointments in the past, the pharmacological approach to cognitive disorders remains an unavoidable option for the multimodal treatment of cognitive disorders. The numerous bioactive molecular pathways that underlie the different cognitive functions constitute many pharmacological targets. Of course, neurotransmission pathways remain important, but other pathways are emerging, such as hormones, neuropeptides, growth factors, transduction pathways, and steroids. The pathways involved in the processes leading to neurodegeneration or dysconnectivity, whether specific or not, remain relevant for pharmacological modulation. The aim of this Special Issue is to review the advances in the pharmacological modulation of bioactive brain pathways for the treatment of cognitive disorders. It will include original articles, reviews of the literature, and methodological developments in both experimental and clinical approaches.

### **Guest Editors**

Prof. Dr. Régis Bordet

Pharmacologie Médicale, Université de Lille, Lille, France

Dr. Thibaut Dondaine

Lille Neuroscience and Cognition Research Center, Université de Lille, Lille, France

Dr. Julie Deguil

Faculty of Medicine, Université de Lille, Lille, France

## Deadline for manuscript submissions

closed (30 November 2023)



## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/141590

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





## **Pharmaceutica**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

### Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

### **Author Benefits**

### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

